Can dabrafenib be used to treat lung adenocarcinoma?

Dabrafenib (Dabrafenib) is a mutant BRAF kinase inhibitor, a research project from Glaxo Smith K’s research, aiming to discover selective inhibitors of mutant BRAF kinase activity for the treatment of solid tumors. It is currently approved for the treatment of BRAF Unresectable or metastatic non-small cell lung cancer with V600E or V600K gene mutations, but currently dabrafenib is not approved for the treatment of lung adenocarcinoma.

Studies in recent years have shown that BRAF V600E mutations also exist in patients with non-small cell lung cancer, and these patients may benefit from dabrafenib treatment. According to the results of some early clinical trials, dabrafenib combined with trametinib has a certain therapeutic effect for patients with non-small cell lung cancer with BRAF V600E mutations. However, clinical trials are ongoing to evaluate dabrafenib in other types of cancer, which may also include lung adenocarcinoma.

The original drug of dabrafenib is relatively expensive and has been covered by medical insurance since it was launched in China. Currently only eligible patients are reimbursed. The price of each box of 50mg*120 capsules may be around around 10,000. The Turkish version of the original drug Dabrafenib sold overseas, Specifications 75mg*120 capsules, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, Specifications produced by Laos Pharmaceutical Factory The price of 75mg*120 tablets per box may be more than 4,000 yuan (the price may fluctuate due to exchange rates).